We combine a growing portfolio of ocular disease models with specialized ocular dosing techniques and imaging methods to comprehensively evaluate PK/PD, distribution and adverse effects of novel ocular therapies and devices.
The Biomere team has validated several ocular disease models using state-of-the-art techniques including in-life imaging and terminal imaging and tissue collections. The team focuses on evaluating PK/PD characteristics and early safety profiles of novel therapies to treat ocular diseases. The Biomere site in the US has a variety of ocular models under development and has interest in collaborative model development on new and unique ocular models. Our combined preclinical and clinical research experience distinctively positions us to support our clients’ preclinical ophthalmic needs.
The Biomere ocular team has deep expertise in a range of dosing techniques in mouse, rat, rabbit and primate models. Most of the dosing methods are applicable to large and small animal species, and include the following local and systemic methods:
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Uveitis is also known as inflammation of the eye where the vascularized middle layer of the eye becomes inflamed resulting in tissue damage and in
